
More Texas children are getting vaccinated early against measles
More Texas parents are opting to vaccinate their babies early against measles, nearly a 4.5-fold increase so far this year compared to 2019, according to the Texas Department of State Health Services.
From January through April, 7,107 children between the ages of 6 months and 11 months were vaccinated for measles, which is typically reserved for infants about to travel internationally or living in a measles outbreak area. Otherwise, doctors usually administer the first dose of the vaccine when they turn 1 year old.
For the same period in 2019, only 1,591 children between 6 months old and 11 months old were vaccinated for measles.
Researchers and public health officials attribute the rise to more awareness and the availability of the earlier vaccination option in a region where there have already been two deaths attributed to measles. They say parents are more fearful now.
The increase comes as the state battles a measles outbreak in West Texas, where 722 cases have been reported, most of them involving children. It is the largest outbreak since 2000..
'It does show that parents really are scared, and that parents don't want to wait,' said Nina Masters, a senior applied research scientist at Truveta, a Washington-based company that is studying Texas' vaccination data. 'They don't want to wait 12 months to get their child vaccinated. They want to wait six months and one day, and they want to do it as soon as they can.'
And, since state data only reflects vaccine information parents voluntarily give to them, the number of babies receiving the vaccine early is probably higher. Masters' company estimates an 11-fold increase in the number of early measles vaccine shots in Texas between 2019 and 2025, according to a study released this week.
The Truveta study found that in March and April of this year, 20% of all first measles vaccine doses given to 2-year-olds and younger were in babies who were 6 months old to 11 months old.
'This is a really big jump,' Masters said.
Increased vaccine uptake is among the reasons local health officials have seen the number of new measles cases drop in recent days. Last week, only nine new cases were reported, the lowest number over a 7-day period since February. Other factors contributing to the slowdown include natural immunity, quick identification of cases by providers and public health workers, and more infected people staying home because of better measles awareness, officials say.
Texas vaccine data typically comes with caveats because it is anything but complete.
Even Truveta's vaccine data doesn't reflect statewide totals since they only access medical records kept by five major health systems in Texas: AdvanetHealth in Central Texas; Baylor Scott & White in Central Texas and Dallas-Fort Worth area; Providence, which operates in El Paso Lubbock and Waco; and Memorial Hermann and CommonSpirit, both in Houston. Together, they represent 90 hospitals and associated ambulatory/outpatient clinics.
Most states automatically record every immunization given unless the patient decides to opt out of the reporting.
Of the 64 immunization registries operating in the United States, 43 have immunization records of all patients unless that patient specifically opts out.
But Texas is in the minority. Patients, or their parents, if they are a minor, have their vaccination data automatically excluded from the state's immunization registry unless they specifically opt in.
So it's not clear what percentage of Texans are included in the state's immunization data.
'You would have to know the total number of people vaccinated to produce the percentage of vaccinated people who have opted into the registry,' said Lara Anton, a spokesperson for the Texas Department of State Health Services. 'We don't know the total number of people who have been vaccinated.'
The state's childhood vaccine schedule includes two measles-mumps-rubella shots by age six with the first administered once a child reaches their first birthday. Even if a child receives their shot early, doctors recommend they still follow the vaccine schedule and receive two more doses.
Because children younger than one have less developed immune systems, the 'zero' or earlier dose is weaker than a regular vaccine and offers just enough protection to cover the child, but not enough to offer lifelong protection, said Katherine Wells, Lubbock's health director.
Wells said if she had a 6-month-old child, she would have them vaccinated with an earlier dose.
For the past few months, Texas health officials have asked parents to consider this earlier dose if they plan to travel or live in the outbreak area or plan to travel internationally.
West Texas public health officials have posted flyers throughout the region and held press conferences and vaccination clinics to encourage more people to vaccinate against measles, which is the most effective way to prevent infection. Pediatricians in West Texas have been emailing and texting patients to let them know they can vaccinate children earlier than 12 months old.
Lubbock, where 53 measles cases have been reported, is 75 miles from Gaines County, where the measles outbreak began in late January. Wells said Wednesday her department has distributed 500 more measles doses than they normally do this year, mostly to children. She said pediatricians in the area are responsible for about another 2,500 more than normal and private physicians have administered most of the early doses to babies.
Measles, once considered eliminated from the United States, is highly contagious and can cause rash and flu-like symptoms but it has more serious complications like brain inflammation and pneumonia and can cause death. In Texas, two school-age girls have died from measles so far.
'I think this does really remind us and help normalize that even though we're in a climate of increased vaccine hesitancy and conversations about changing vaccine policies and vaccine access, the majority of parents still believe in vaccination and vaccinate their children,' Masters said.
First round of TribFest speakers announced! Pulitzer Prize-winning columnist Maureen Dowd; U.S. Rep. Tony Gonzales, R-San Antonio; Fort Worth Mayor Mattie Parker; U.S. Sen. Adam Schiff, D-California; and U.S. Rep. Jasmine Crockett, D-Dallas are taking the stage Nov. 13–15 in Austin. Get your tickets today!
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Sydnexis Announces European Commission Approval of SYD-101, the First and Only Pharmaceutical Treatment for Slowing the Progression of Pediatric Myopia
Exclusive-Licensing Partner Santen Will Commercialize SYD-101 Under the Brand Name Ryjunea® in the European Union DEL MAR, Calif., June 05, 2025--(BUSINESS WIRE)--Sydnexis, Inc., ( a pre-commercial stage biopharmaceutical company today announced that the European Commission (EC) has granted marketing authorization for SYD-101, the company's proprietary low-dose atropine formulation, for slowing the progression of pediatric myopia. As the first and only approved pharmaceutical treatment option to treat myopia progression in EU countries, this approval marks a significant advancement in pediatric eye care. The approval is backed by data from the STAR study, Sydnexis' pivotal Phase 3 clinical trial evaluating its proprietary low-dose atropine formulation to slow the progression of pediatric myopia and the risk of associated co-morbidities in children 3 to 14 years old at treatment initiation. "This marks a significant milestone for Sydnexis and, most importantly, for pediatric patients with progressive myopia, their families, and physicians as the first and only approved pharmaceutical treatment option in Europe," said Perry Sternberg, Chief Executive Officer of Sydnexis. "This approval is an endorsement of the potential benefit SYD-101 can provide to millions of patients globally and reinforces the critical importance of early intervention." The marketing approval from the EC follows the recent positive opinion from the Committee for Medicinal Products for Human Use (CHMP). Santen, a Japan-based company specialized in eye health, offering innovative products and services in over 60 countries worldwide, licensed the rights from Sydnexis to commercialize SYD-101 in the regions of Europe, Middle East, and Africa (EMEA) and will launch SYD-101 under the brand name Ryjunea. "The EU approval of SYD-101 is a recognition of the compelling safety and efficacy data generated from our landmark STAR study," said Patrick Johnson, Ph.D., President of Sydnexis. "This validates the potential benefit that SYD-101 can provide to pediatric myopes in Europe and we are excited about our continued interactions with the Food and Drug Administration (FDA) leading up to our October 23 PDUFA date." Myopia is the most common eye disease in children, impacting approximately one-third of children and adolescents worldwide. By 2050, global prevalence is projected to increase and affect more than 740 million children and adolescents and 5 billion people in total. Once considered a benign refractive condition, even at low levels, myopia is now associated with many serious irreversible sight-threatening co-morbidities later in life. "As a Pediatric Ophthalmologist with a rapidly growing number of myopia patients around the world, the EU approval of SYD-101 is truly exciting and it provides an important new tool for physicians to combat this global epidemic," said Dr. Donny Suh, Gavin Herbert Eye Institute, University of California at Irvine. "The benefits of low-dose atropine have long been recognized in the eye care community, but we now finally have an approved and thoroughly vetted treatment option. This marks a new era in our ability to slow the progression of myopia and protect the vision of millions of children worldwide." About Sydnexis, Inc.: Founded in 2014, Sydnexis, Inc. ( is a privately held, pre-commercial stage biopharmaceutical company based in San Diego, California. Sydnexis recently completed its three-year primary endpoint in the pivotal Phase 3 clinical trial evaluating its proprietary low-dose atropine formulation to slow progression of pediatric myopia and the risk of associated co-morbidities. The Phase 3 clinical trial is now completing the fourth-year randomized withdrawal for exploratory endpoints and third year results will be announced upon completion of the fourth year of the study. The company is venture-backed by four major investors: Visionary Ventures, RA Capital, Longitude Capital, and Bluestem Capital. View source version on Contacts For media inquiries, please contact: media@
Yahoo
an hour ago
- Yahoo
Corrupt Edinburgh NHS manager jailed for eight years over £6m contracts
Four men have been jailed for a total of 29 years over the awarding of NHS contracts worth £6million. Alan Hush, 68, Adam Sharoudi, 41, Gavin Brown, 48, and Gavin Cox, 60, were convicted by a jury following an investigation at health boards across Scotland. Hush, telecommunications manager at NHS Lothian and then NHS Scotland's video conferencing manager, was sentenced to eight years in jail. READ MORE: Edinburgh man's touching tribute for best pal after his unexpected death at 38 READ MORE: 'Maggots burst from tin of tuna I was about to feed my baby - I can never eat touch it again' Sharoudi and Brown, directors of Ayrshire-based telecommunications firm Oricom Ltd, were imprisoned for eight years and seven years respectively. Cox, who held the post of head of IT and infrastructure at NHS Lanarkshire, will spend six years in prison. Sineidin Corrins, Deputy Procurator Fiscal for Specialist Casework at the Crown Office and Procurator Fiscal Service (COPFS), said: 'This is an outstanding result for justice in Scotland. 'As prosecutors, we have shown an unwavering commitment to pursuing and investigating this matter. This was a betrayal of public trust. 'These four men colluded to create a sophisticated criminal scheme. The public will rightly be shocked by the scale of their criminality. The scale of this offending against our public health service is particularly egregious. 'The systematic abuse of position by public officials, who accepted inappropriate benefits including cash, holidays and entertainment in exchange for contract advantages, strikes at the heart of public trust. 'It serves as a reminder that procurement processes exist to ensure fair competition and value for public money. When these processes are corrupted, all of society bears the cost. 'The prosecutorial journey has been complex and demanding. It required forensic examination of thousands of documents, hundreds of witness statements, and detailed financial analyses to establish the full extent of this criminal activity. Sign up for Edinburgh Live newsletters for more headlines straight to your inbox 'The digital evidence, particularly text messages and emails exchanged between the accused, proved pivotal in exposing the true nature of these arrangements. 'This was a meticulous investigation and one which reflects the enduring partnership working between specialist Crown Office prosecutors, NHS Counter Fraud Services and Police Scotland who worked tirelessly over many years. 'Their unflinching dedication to serving the interests of justice, regardless of complexity or duration, deserves recognition. 'The Crown Office and Procurator Fiscal Service has worked closely with these specialist reporting agencies to ensure justice has been served. 'This case demonstrates clearly that those who indulge in corrupt practices for their own personal gain will be brought to book regardless of the time it takes to bring offenders to justice. Join Edinburgh Live's Whatsapp Community here and get the latest news sent straight to your messages. 'The Proceeds of Crime proceedings that will follow demonstrate our ongoing commitment to ensuring that crime does not pay and that illicitly obtained funds are recovered where possible.' All four individuals will now be subject to confiscation action under Proceeds of Crime legislation to recover monies illegally obtained. Brown and Sharoudi were also banned from being company directors for 10 years.


Business Wire
an hour ago
- Business Wire
Sydnexis Announces European Commission Approval of SYD-101, the First and Only Pharmaceutical Treatment for Slowing the Progression of Pediatric Myopia
DEL MAR, Calif.--(BUSINESS WIRE)--Sydnexis, Inc., ( a pre-commercial stage biopharmaceutical company today announced that the European Commission (EC) has granted marketing authorization for SYD-101, the company's proprietary low-dose atropine formulation, for slowing the progression of pediatric myopia. As the first and only approved pharmaceutical treatment option to treat myopia progression in EU countries, this approval marks a significant advancement in pediatric eye care. The approval is backed by data from the STAR study, Sydnexis' pivotal Phase 3 clinical trial evaluating its proprietary low-dose atropine formulation to slow the progression of pediatric myopia and the risk of associated co-morbidities in children 3 to 14 years old at treatment initiation. 'This marks a significant milestone for Sydnexis and, most importantly, for pediatric patients with progressive myopia, their families, and physicians as the first and only approved pharmaceutical treatment option in Europe,' said Perry Sternberg, Chief Executive Officer of Sydnexis. 'This approval is an endorsement of the potential benefit SYD-101 can provide to millions of patients globally and reinforces the critical importance of early intervention.' The marketing approval from the EC follows the recent positive opinion from the Committee for Medicinal Products for Human Use (CHMP). Santen, a Japan-based company specialized in eye health, offering innovative products and services in over 60 countries worldwide, licensed the rights from Sydnexis to commercialize SYD-101 in the regions of Europe, Middle East, and Africa (EMEA) and will launch SYD-101 under the brand name Ryjunea. 'The EU approval of SYD-101 is a recognition of the compelling safety and efficacy data generated from our landmark STAR study,' said Patrick Johnson, Ph.D., President of Sydnexis. 'This validates the potential benefit that SYD-101 can provide to pediatric myopes in Europe and we are excited about our continued interactions with the Food and Drug Administration (FDA) leading up to our October 23 PDUFA date.' Myopia is the most common eye disease in children, impacting approximately one-third of children and adolescents worldwide. By 2050, global prevalence is projected to increase and affect more than 740 million children and adolescents and 5 billion people in total. Once considered a benign refractive condition, even at low levels, myopia is now associated with many serious irreversible sight-threatening co-morbidities later in life. 'As a Pediatric Ophthalmologist with a rapidly growing number of myopia patients around the world, the EU approval of SYD-101 is truly exciting and it provides an important new tool for physicians to combat this global epidemic,' said Dr. Donny Suh, Gavin Herbert Eye Institute, University of California at Irvine. 'The benefits of low-dose atropine have long been recognized in the eye care community, but we now finally have an approved and thoroughly vetted treatment option. This marks a new era in our ability to slow the progression of myopia and protect the vision of millions of children worldwide.' About Sydnexis, Inc.: Founded in 2014, Sydnexis, Inc. ( is a privately held, pre-commercial stage biopharmaceutical company based in San Diego, California. Sydnexis recently completed its three-year primary endpoint in the pivotal Phase 3 clinical trial evaluating its proprietary low-dose atropine formulation to slow progression of pediatric myopia and the risk of associated co-morbidities. The Phase 3 clinical trial is now completing the fourth-year randomized withdrawal for exploratory endpoints and third year results will be announced upon completion of the fourth year of the study. The company is venture-backed by four major investors: Visionary Ventures, RA Capital, Longitude Capital, and Bluestem Capital.